$ELVN SEC Filings

Filed On	Filing
21 Oct 2026	Form 4: Hohl Benjamin, CHIEF FINANCIAL OFFICER Received 6,018 shares by exercise or conversion ($89.4K) · Sold 6,018 shares ($232K)
21 Oct 2026	Form 4: Collins Helen Louise, CHIEF MEDICAL OFFICER Received 5,000 shares by exercise or conversion ($12.4K) · Sold 5,000 shares ($192K)
19 Oct 2026	144
16 Oct 2026	Form 4: Ball Kristine M, Director Granted 23,394 Stock Option (right to buy)
16 Oct 2026	Form 3: Ball Kristine M, Director No securities owned
14 Oct 2026	8-K: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers; Regulation FD Disclosure Accomplished biopharmaceutical executive with extensive experience in corporate strategy, finance and commercial readiness
05 Oct 2026	Form 4: Garland J. Scott, Director Received 13,000 shares by exercise or conversion ($201K) · Sold 13,000 shares ($607K)
01 Oct 2026	144
21 Sep 2026	Form 4: Hohl Benjamin, CHIEF FINANCIAL OFFICER Received 3,982 shares by exercise or conversion ($59.1K) · Sold 6,018 shares ($303K)
21 Sep 2026	Form 4: Collins Helen Louise, CHIEF MEDICAL OFFICER Received 5,000 shares by exercise or conversion ($12.4K) · Sold 5,000 shares ($252K)
17 Sep 2026	144
04 Sep 2026	144
19 Aug 2026	Form 4: Hohl Benjamin, CHIEF FINANCIAL OFFICER Sold 6,018 shares ($353K)
19 Aug 2026	Form 4: Collins Helen Louise, CHIEF MEDICAL OFFICER Received 5,000 shares by exercise or conversion ($12.4K) · Sold 5,000 shares ($293K)
06 Aug 2026	Form 4: Derynck Mika K, Director Received 158,795 shares by exercise or conversion ($1.72M) · Sold 158,795 shares ($9.56M)
06 Aug 2026	SCHEDULE 13G/A
05 Aug 2026	10-Q
05 Aug 2026	8-K: Results of Operations and Financial Condition
04 Aug 2026	144
21 Jul 2026	Form 4: Hohl Benjamin, CHIEF FINANCIAL OFFICER Received 1,072 shares by exercise or conversion ($2.66K) · Sold 6,018 shares ($317K)

Comments